Aptuit and Dimension Therapeutics partner to advance AAV gene therapies

Activities have commenced for three gene therapy programmes in rare disease indications

Aptuit, a premier global drug discovery and development CRO, and Dimension Therapeutics, a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, have announced a strategic partnership agreement under which Aptuit will support GLP IND-enabling studies for select rare disease programmes at Dimension.

Three key integrated development projects have initiated under the partnership.

Jonathan Goldman, Chief Executive Officer, Aptuit, stated: ‘This partnership is designed to accelerate select late preclinical-stage programmes at Dimension in a high-quality environment, supported by a culture of scientific excellence and innovation. At Aptuit, we have deep scientific expertise in the development of compounds that rely on complex molecular and cellular biology, and are able to provide fully integrated solutions for IND programmes.’

‘This best-in-class partnership builds upon Aptuit's scientific excellence in integrated IND development in the exciting area of gene therapies. In particular, we plan to ensure full and timely resourcing of these programmes to increase the probability of success, and reduce both time and cost,’ he added.

Dr Annalisa Jenkins, MBBS, FRCP, Chief Executive Officer of Dimension Therapeutics, commented: ‘We are very pleased to announce the partnership with Aptuit. We share a common culture of scientific excellence and commitment to quality research and development. This alliance will allow select priority preclinical programmes to progress effectively to IND, leveraging our joint expertise in the development of viral vector-mediated assets.’

Companies